Skip to the main content

Gynaecologia et perinatologia : journal for gynaecology, perinatology, reproductive medicine and ultrasonic diagnostics, Vol. 17 No. 2, 2008.

Review article

THROMBOEMBOLIC DISEASE IN PREGNANCY

Darko Husar ; Privatna ginekološka ordinacija Darko Husar, Zagreb, Hrvatska
Josip Đelmiš ; Klinika za ženske bolesti i porode Kliničkog bolničkog centra u Zagrebu, Zagreb, Hrvatska

Full text: croatian pdf 101 Kb

page 77-82

downloads: 1.674

cite

Abstract

Fatal pulmonary embolism remains the most common cause of mortality among pregnant women in many Western countries. About high risk for venous thromboembolism during pregnancy we know for centuries. The physiological changes of pregnancy produce a hypercoagulable state that increases the risk of venous thromboembolism (VTE). Women with inherited or acquired thrombophilias are at particulary high risk of VTE during pregnancy, and throm¬boprophylaxis may be advisable in some cases. Thrombophilia is also associated with complications of pregnancy, including fetal loss, pre-ecclampsia, intra-uterine growth restriction, and placental abruption. The antithrombotic agents available for the prevention and treatment of VTE during pregnancy, and pregnancy complications, include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin. Vitamin K antagonists are contraindicated in pregnancy. The efficacy and safety of LMWH have been demonstrated for the prevention and treatment of the VTE in pregnancy. LMWH is today therapy of the choice for VTE and its complications in pregnancy. LMWH replaced UFH ¬because of its higher security and less side effects.

Keywords

pregnancy; thrombophilia; venous thrombosis; low-molecular-weight heparin

Hrčak ID:

62099

URI

https://hrcak.srce.hr/62099

Publication date:

1.6.2008.

Article data in other languages: croatian

Visits: 5.229 *